Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC7A5 | Q01650 | 6/20 | 0.64 |
| ▸ | NOS3 | P29474 | 3/20 | 0.62 |
| ▸ | NOS1 | P29475 | 3/20 | 0.62 |
| ▸ | NOS2 | P35228 | 3/20 | 0.62 |
| ▸ | ALPI | P09923 | 1/20 | 0.48 |
| ▸ | PKM | P14618 | 1/20 | 0.48 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.48 |
| ▸ | XIAP | P98170 | 1/20 | 0.48 |
| ▸ | GRIA2 | P42262 | 1/20 | 0.47 |
| ▸ | AURKA | O14965 | 1/20 | 0.47 |
| ▸ | RPS6KB1 | P23443 | 1/20 | 0.47 |
| ▸ | NPY1R | P25929 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.44 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.44 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3050840 | 1.00 | SLC7A5 (0.64) | SLC7A5NOS3NOS1NOS2ALPI | |
| SCHEMBL2367419 | 0.89 | SLC7A5 (0.50) | SLC7A5NOS3NOS1NOS2AURKA | |
| SCHEMBL27554182 | 0.86 | SLC7A5 (0.46) | SLC7A5NOS3NOS1NOS2AURKA | |
| SCHEMBL20215005 | 0.85 | AURKA (0.47) | SLC7A5NOS3NOS1NOS2AURKA | |
| SCHEMBL16856591 | 0.85 | AURKA (0.47) | SLC7A5NOS3NOS1NOS2AURKA | |
| SCHEMBL20204195 | 0.85 | AURKA (0.47) | SLC7A5NOS3NOS1NOS2AURKA | |
| SCHEMBL10884035 | 0.85 | NOS3 (0.48) | SLC7A5NOS3NOS1NOS2AURKA | |
| SCHEMBL2309189 | 0.84 | PPARG (0.55) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL21689917 | 0.84 | PPARG (0.55) | SLC7A5ALPIPKMPTGS1XIAP | |
| SCHEMBL2617177 | 0.84 | PPARG (0.55) | SLC7A5ALPIPKMPTGS1XIAP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8076285-B2 | Lysobactin amides | AICURIS GMBH & CO. KG (DE) | 2011-12-13 | — | — | US | disclosed |
| EP-2007794-B1 | LYSOBACTIN AMIDES | AICURIS GMBH & CO KG (DE) | 2011-09-14 | — | — | EP | disclosed |
| US-7718611-B2 | Cyclic nonapeptide amides | AICURIS GMBH & CO. KG (DE) | 2010-05-18 | — | — | US | disclosed |
| US-20090203582-A1 | LYSOBACTIN AMIDES | BAYER HEALTHCARE AG (DE) | 2009-08-13 | — | — | US | disclosed |
| US-20080070884-A1 | Antibiotics; novel class of cell wall biosynthesis inhibitors without cross-resistances to known classes of antibiotics; active analogs of lysobactin with a higher ring stability | AICURIS GMBH & CO. KG (DE) | 2008-03-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080070884-A1 | Antibiotics; novel class of cell wall biosynthesis inhibitors without cross-resistances to known classes of antibiotics; active analogs of lysobactin with a higher ring stability | AAAS, PGLS, NRDC | SLC7A5 337/4885NOS3 3453/4885NOS1 2016/4885 |
| US-20090203582-A1 | LYSOBACTIN AMIDES | AADAT, HAMP, DLST | SLC7A5 298/4885NOS3 4311/4885NOS1 4189/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.